The second version of the MyoCycle, a functional electrical stimulation (FES) bike designed for people with motor disabilities, including Parkinson’s disease, is now available in the U.S. after winning the needed go-ahead from federal regulators. The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to developer…
Alpha Motor Corporation, an electric vehicle company based in Irvine, California, will donate 100% of net proceeds of sales from its NFT fundraiser to the Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its research programs advancing work into Parkinson’s disease. The online event features…
Boston Scientific has received approval from the U.S. Food and Drug Administration (FDA) for its Vercise Neural Navigator with STIMVIEW XT, a visualization software that allows doctors to see in real-time the location of leads, or electrodes, within the brain of a Parkinson’s disease patient undergoing deep brain stimulation…
Nitrase Therapeutics has received a second grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance the company’s research on nitrated alpha-synuclein, a new potential biomarker to help predict and diagnose Parkinson’s disease. “MJFF is the leading research accelerator for Parkinson’s disease treatments, and…
Kurarinone, a compound derived from a plant in the pea family and part of traditional Chinese medicine, was found to ease Parkinson-like behaviors in a mouse model of Parkinson’s disease. This compound can lessen neuroinflammation, or inflammation in the brain, by targeting soluble epoxide hydrolase (sEH), an enzyme that…
According to an online survey, the COVID-19 pandemic negatively affected the caregivers of patients with Parkinson’s disease, with a large proportion of caregivers reporting feeling sadness and anxiety. The findings of the study, “COVID-19’s Impact on Burden and Nutrition for Family Caregivers of People With Parkinson’s Disease,”…
An almost €2 million (about $2.3 million) EU-funded project is advancing the understanding of how damaged or abnormal cell parts are removed at the synapses, a process known as synapse-specific autophagy, and how defects in this mechanism contribute to neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s. Synapses,…
Eight grants worth a total of $575,000 were awarded by the McCamish Parkinson’s Disease Innovation Program to research teams at Georgia Tech and Emory University advancing projects into Parkinson’s disease. “These grants are specifically focused on technology-driven research for understanding, treating, and curing Parkinson’s disease,” Garrett Stanley, PhD, professor…
In mice with a harmful mutation in the leucine-rich repeat protein kinase 2 (LRRK2) gene, one of the most common genetic causes of Parkinson’s disease, treatment with a small molecule compound restored the recycling of damaged mitochondria — the cells’ powerhouses — from dopamine-producing nerve cells. A failure…
BiomeBank is launching a trial in Australia to test whether its fecal microbiota transplantation therapy, which works to replenish gut bacteria, is a safe, tolerable and effective treatment of Parkinson’s disease symptoms, such as constipation. The trial is being conducted in collaboration with the Royal Adelaide and Queen Elizabeth hospitals…
Get regular updates to your inbox.